Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Sevelda

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Clinical Breast Cancer|May 22, 2002
Young age as an independent adverse prognostic factor in premenopausal patients with breast cancerPeter C Dubsky, Michael F X Gnant, Susanne Taucher, et al.
Breast Cancer Research and Treatment|July 29, 2008
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancerRupert Bartsch, Brigitte Mlineritsch, Michael Gnant, et al.
Expert Review of Vaccines|December 13, 2024
Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE?Eugenia Karamousouli, Ugne Sabale, Stefano Valente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Vaccine|August 25, 2010
Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigensAndreas L Meinke, Beatrice M Senn, Zehra Visram, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study GroupPeter C Dubsky, Raimund Jakesz, Brigitte Mlineritsch, et al.
Lancet (London, England)|June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialMichael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
British Journal of Cancer|March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Breast Cancer|May 22, 2002
Young age as an independent adverse prognostic factor in premenopausal patients with breast cancerPeter C Dubsky, Michael F X Gnant, Susanne Taucher, et al.
Breast Cancer Research and Treatment|July 29, 2008
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancerRupert Bartsch, Brigitte Mlineritsch, Michael Gnant, et al.
Expert Review of Vaccines|December 13, 2024
Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE?Eugenia Karamousouli, Ugne Sabale, Stefano Valente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Vaccine|August 25, 2010
Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigensAndreas L Meinke, Beatrice M Senn, Zehra Visram, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study GroupPeter C Dubsky, Raimund Jakesz, Brigitte Mlineritsch, et al.
Lancet (London, England)|June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialMichael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
British Journal of Cancer|March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Pageof 3